Paris, France (November 2002) - AUREUS PHARMA, a leading knowledge management-based drug discovery company and a solution provider for the life sciences industry, today announces that it has entered into an agreement with SERVIER to build up an ADMET (absorption, distribution, metabolism, elimination and toxicity) database and related tools. This database gives subscribers access to information on all major ADMET data allowing to detect potential pitfalls related to negative ADMET properties and optimize the drug development value chain. SERVIER researchers will be able to exploit all ADMET-related information from a single, integrated knowledgemanagement platform. This integrated computational solution will facilitate the generation of powerful drug interaction prediction models, identifying at early stages the most promising and safe clinical development candidates. The ADMET system, after the 7-TM database is the second product developed by AUREUS Pharma. "We believe that in silico predictive models are key elements in a valuable drug discovery and development process. This agreement validates the high potential of AUREUS PHARMA technologies based on an efficient exploitation of current experimental knowledge. We are delighted to associate SERVIER in our project to build an integrated platform dedicated to the discovery of safer and more efficient drugs." said Dr. André Michel, President of AUREUS PHARMA.
About SERVIER
Since its creation in 1954, Servier, the leading French independent pharmaceutical company, has been dedicating a large part of its activity to Research and Development. Each year, almost 25% of its turnover is invested in R&D. Today, 30 Servier drugs are available to the medical community. They were all developed by Servier Research, which has produced over 35.000 different molecules protected by over 15.000 patents. Servier's main areas of therapeutic interest are cardiovascular diseases, neurosciences and psychiatry, cancer, diabetes, gynaecology, and rheumatology. In March 2002, Servier received the Prix Galien, in recognition of "the quantity, the quality and the dynamism of the therapeutic research carried out, both within the Servier Group and in collaboration with numerous French and international research teams". Servier has developed important national and international research partnerships, with the INSERM, the CNRS, various universities and biotech and bioinformatics companies. Servier is the main partner of the INSERM in terms of quantity of research contracts in progress.
About AUREUS-PHARMA,
AUREUS PHARMA, headquartered in Paris, France, is a privately held leading knowledge management-based drug discovery company and a solution provider for the life sciences industry founded in 2000. AUREUS PHARMA proposes a novel solution thanks to an integrated set of technologies, combining a computerized knowledge management systems with experimental methods in order to accelerate new drug discovery. This mission fits with the need to innovate in therapeutic target identification and to discover safer and more specific drugs. Visit the company's Web site: www.aureus-pharma.com.
